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Abstract 
Dengue is an important global threat caused by dengue virus (DENV) that records an estimated 
390 million infections annually. Despite the availability of CYD-TDV as a commercial vaccine, its 
long-term efficacy against all four dengue virus serotypes remains unsatisfactory. There is 
therefore an urgent need for the development of antiviral drugs for the treatment of dengue. 
Peptide was once a neglected choice of medical treatment but it has lately regained interest from 
the pharmaceutical industry following pioneering advancements in technology. In this review, the 
design of peptide drugs, antiviral activities and mechanisms of peptides and peptidomimetics 
(modified peptides) action against dengue virus are discussed. The development of peptides as 
inhibitors for viral entry, replication and translation is also described, with a focus on the three 
main targets, namely, the host cell receptors, viral structural proteins and viral non-structural 
proteins. The antiviral peptides designed based on these approaches may lead to the discovery of 
novel anti-DENV therapeutics that can treat dengue patients. 
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Introduction 
Dengue is a mosquito-borne disease caused by 
the infection of dengue virus (DENV). It has been 
estimated that 390 million dengue infections occur 
annually, of which 96 million manifest clinically [1]. 
Before 1970, only nine countries experienced dengue 
epidemics. Currently, dengue is endemic in more than 
100 countries, primarily in tropical and sub-tropical 
countries [2]. There are four dengue virus serotypes, 
DENV-1-4, which are genetically and antigenically 
distinct, although each serotype elicits a similar range 
of disease manifestations during infection [3]. In 
humans, dengue infection causes a spectrum of 
illnesses ranging from asymptomatic, fever, rash, joint 
pain and other mild symptoms to life-threatening 
dengue haemorrhagic fever (DHF) and dengue shock 
syndrome (DSS) [4]. Infection with one DENV 
serotype induces lifelong immunity against the 
homologous serotype but not against the other three 
heterologous serotypes. In fact, studies have shown 
that secondary infection with a different DENV 
serotype is an important risk factor in causing more 
severe complications, such as DHF and DSS, due to a 
phenomenon designated as antibody dependent 
enhancement (ADE) or the original antigenic sin [5-7]. 
One of the strategies that has been undertaken to 
halt DENV infection is by vector control. Aedes aegypti 
and Aedes albopictus are the primary transmission 
vectors for DENV [8]. Strategies such as fogging and 
the release of genetically modified mosquitoes which 
could lead to the production of fewer progenies [9] 
have failed to lessen the mosquito population, as 
witnessed by the emergence of new dengue cases in 
places that were dengue-free or had less dengue cases 
in the past [10-12]. While active research on vaccine 
development for dengue has been ongoing for the 
past few decades, the development of vaccines has 
been held back by several challenges. The major 
constraints for dengue vaccine development include 
the lack of good animal models, the complexity of 
developing a vaccine against all four antigenically 
distinct DENV serotypes, as well as the need to 
achieve balanced tetravalent responses that could 
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exhibit significant immunity against all four viruses 
without the adverse effects of ADE or original 
antigenic sin [13]. The first dengue vaccine, 
Dengvaxia®, (CYD-TDV, chimeric yellow fever 
virus-tetravalent dengue vaccine) developed by 
Sanofi Pasteur was licensed in December 2015 in 
Mexico. It is a live-attenuated tetravalent vaccine 
comprising structural proteins (pre-membrane and 
envelope proteins) of DENV based on the yellow 
fever 17D virus backbone [14, 15]. The approved 
regimen involves three doses, given at the 0th, 6th and 
12th months, for individuals between 9-45 years of age. 
Outcomes from phase III clinical trials showed that 
the vaccine successfully reduced dengue 
hospitalizations by 80%. However, its average efficacy 
against DENV was low, especially against DENV-1 at 
approximately 50% and against DENV-2 at 39%. Its 
average efficacy against DENV-3 and DENV-4, 
meanwhile, was slightly higher at 75% and 77%, 
respectively [16, 17]. Furthermore, previous clinical 
trials revealed that CYD-TDV vaccination caused 
elevated risks of hospitalization for children less than 
nine years of age [18]. The World Health Organization 
has therefore recommended the use of CYD-TDV 
vaccine only in countries where epidemiological data 
indicated a high burden of dengue [19].  
The lack of efficient vector control strategies and 
the uncertainty of long-term protective efficacy of 
CYD-TDV vaccine against all four DENV serotypes 
call for an urgent need for dengue therapeutics, 
especially in endemic countries with poor resource 
setting. There are no antiviral drugs available and at 
present, supportive treatment with emphasis on fluid 
therapy and close clinical monitoring during the 
critical phase of illness are the only course of action 
for dengue disease. Many antiviral candidates have 
failed to reach clinical trials due to their poor 
selectivity and physiochemical or pharmacokinetic 
properties [20]. Although nucleoside analogs, such as 
NITD-008 and balapiravir, have entered preclinical 
animal safety study and clinical trials, they were 
terminated due to lack of potency [21]. Balapiravir, for 
instance, did not improve the clinical and virological 
parameters in patients in the phase II clinical trial, 
although it was shown to have good in vitro antiviral 
activities with EC50 values of 1.3–3.2 µM in DENV 
infection assays using primary human macrophages 
[21]. Treatment of DENV-infected mice with another 
nucleoside analog NITD-008, on the other hand, 
completely prevented mice death, but severe adverse 
events were observed in rats and dogs after two 
weeks of oral dosing [20, 22]. Likewise, other 
anti-DENV candidates, including chloroquine, 
prednisolone, celgosivir and lovastatin, have gone 
through clinical trials but failed to meet the defined 
primary end points, whereby neither significant 
viremia nor evidence of beneficial effects on clinical 
manifestations was observed [23-26]. At present, two 
candidates, namely ivermectin and ketotifen, are 
undergoing clinical trials (trial number NCT02045069 
and NCT02673840, respectively). However, their 
long-term clinical efficacies remain to be determined. 
In contrast to small molecules, peptides are generally 
known to have high selectivity and possess relatively 
safe characteristics which make them attractive 
pharmacological candidates [27]. Due to their 
attractive pharmacological profiles, this review will 
highlight the current status and the rational drug 
design of antiviral peptides and peptidomimetics as 
therapeutics for dengue. 
Dengue Virus (DENV)  
DENV is an enveloped, positive, single-stranded 
(ss) RNA virus classified under the genus Flavivirus of 
the Flaviridae family [28]. Other closely related viruses 
classified under the Flavivirus include yellow fever 
virus (YFV), west nile virus (WNV), japanese 
encephalitis virus (JEV) and zika virus. The dengue 
virion is a spherical particle, approximately 50 nm in 
diameter with envelope (E) and precursor-membrane 
(prM) / membrane (M) proteins located on its surface, 
while the capsid (C) proteins sit underneath the lipid 
bilayer, encapsulating the viral genome [29]. The 
DENV genome (~11 kb) constitutes a single open 
reading frame (ORF), encoding three structural 
proteins (C, prM/M and E proteins) followed by 
seven non-structural (NS) proteins (NS1, NS2A and 
2B, NS3, NS4A and 4B, NS5) (Figure 1) [30]. The 
translated polyprotein is then cleaved by cellular 
signal peptidases and virally encoded protease (NS2B 
and NS3) to generate individual proteins. The 
structural proteins form the viral particle while the 
non-structural proteins participate in replication and 
invasion of the immune system [30]. To design 
peptides with therapeutic potential against dengue 
virus, it is necessary to understand the viral 
replication cycle.  
DENV infection in humans starts with a 
DENV-infected mosquito bite. DENV can replicate in 
a wide spectrum of cells, including liver, spleen, 
lymph node, kidney and other organs [31, 32], but 
monocytes, macrophages and dendritic cells (DC) 
have been shown to be the major targets for DENV 
[33, 34]. The life cycle of dengue virus is initiated by 
the virus attachment through the interaction between 
viral surface proteins and attachment/receptor 
molecules on the surface of the target cell (Figure 2). 
Receptor recognition is believed to be mediated by the 
domain III of E protein to enable the virus to enter into 
host cells by receptor-mediated, clathrin-dependent 
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endocytosis (primary method) [35, 36]. However, 
studies have also shown that viral entry could occur 
by the direct fusion of the virus and host cells [37-39]. 
After internalization, dissociation of the E 
homodimers takes place as a result of the acidic 
environment in the endosome. Subsequently, domain 
II of the E protein will project outwardly and the 
hydrophobic fusion loop in domain II will insert itself 
into the endosomal membrane [40, 41]. This will then 
trigger domain III to fold back and force the virus 
particle and endosomal membrane to move towards 
each other and fuse together [42, 43]. The fusion of the 
virus with vesicular membranes would then release 
the nucleocapsid into cytoplasm, resulting in genome 
uncoating [44]. Subsequently, the viral RNA genome 
is released. The viral RNA is translated into a single 
polyprotein and processed co- and 
post-translationally by cellular and virus-derived 
proteases into three structural proteins and seven NS 
proteins (Figure 1). Upon protein translation, the NS 
proteins initiate viral genome replication at the 
intracellular membranes, resulting in the production 
of more viral RNA strands [45]. Then, the newly 
synthesized RNA is packed by C proteins to form the 
nucleocapsid [46]. The prM and E proteins, on the 
other hand, form heterodimers that oriented into the 
lumen of ER and are believed to induce a curved 
surface lattice which guides virion budding [47]. 
Hence, the virus assembles and buds from the ER 
before migrating to the trans-Golgi for maturation 
process. The slightly acidic pH of the trans-Golgi 
network prompts the dissociation of prM/E 
heterodimers to form 90 dimers with prM capping the 
fusion peptide located at the domain II of the E 
protein [48]. This is followed by the cleavage of the 
prM at Arg-X-(Lys/Arg)-Arg by cellular 
endoprotease (furin), (where X is any amino acid) to 
produce membrane-associated M and “pr” peptide 
[49, 50]. Both prM and the “pr” will act as chaperones 
to stabilize the E protein during the secretory 
pathway by preventing premature membrane fusion. 
At the end, the “pr” peptide will dissociate upon the 
release of the progeny by exocytosis [45]. 
Development of Peptides as Therapeutics 
Peptides are biologically active molecules 
comprising the combination of at least two amino 
acids through a peptide bond. In contrast to large 
proteins, they are smaller in size and are considered to 
contain less than 100 amino acid residues. Peptides 
are known to have attractive pharmacological profiles 
due to their highly selective and relatively safe 
characteristics [27]. They readily exist in the human 
body and exert diverse biological roles, 
predominantly as signalling and regulatory molecules 
in a variety of physiological processes [51]. In the past, 
peptides were held back in the drug development 
pipelines due to their instability, whereby they could 
be easily degraded by at least 569 proteases in the 
human body [52]. Nevertheless, a number of 
technological breakthroughs and advancements have 
reversed the situation. This has resulted in the spark 
of interest in peptide drug development. Current 
technologies have allowed the modification of 
peptides to create artificial variants with improved 
stability and overcome pharmacodynamic 
weaknesses. For instance, advances in 
automated-liquid handling devices, synthetic peptide 
synthesis, mass spectrometry and in silico drug design 
have allowed high-throughput drug screening. In 
addition, advances in peptide manipulations such as 
synthesis of D-amino acids, cyclic peptides, 
incorporation of chemicals and nanocarriers have 
further increased the bioavailability of peptides [53]. 
Currently, ample examples of efficacious and safe 
peptide drugs are available in the market [54-57]. 
Great success has been achieved for the peptide drug 
FuzeonTM (enfuvirtide), a synthetic peptide that blocks 
viral fusion by binding to the gp41 (polypeptide 
chain) of the human immunodeficiency virus (HIV) 
type-1 envelope protein [55]. It is the only antiviral 
peptide which has been commercialised. Other 
antimicrobial peptide candidates, such as MU1140, 
Arenicin, IMX924, Novexatin and Lytixar, are being 
evaluated in the preclinical and clinical trials [58, 59]. 
Myrcludex B, an anti-Hepatitis B and Hepatitis D 
 
Figure 1. Schematic diagram of the DENV genome showing structural and non-structural polyproteins that are encoded by the DENV genome. 
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peptide targeting sodium taurocholate 
co-transporting polypeptide (NTCP) of liver cells, is 
also being studied in a phase II clinical trial [60].  
At present, the value of global peptide 
therapeutics market is predicted to increase from 
US$21.3 billion (2015) to US$46.6 billion in the year 
2024 [61]. There are at least 60 therapeutic peptides 
that have been approved by the US Food and Drug 
Administration (FDA) and approximately 140 peptide 
therapeutics are being evaluated in clinical trials [62]. 
In 2011, 25 of the US-approved peptide drugs 
accounted for the global sale of over US$14.7 billion, 
while Victoza®, Zoladex®, Sandostatin®, Lupron® 
and Copaxone® each had global sales of over 
US$1,000 million [63]. Some other examples of 
therapeutic peptides include glucagon-like peptide-1 
(GLP-1) and analogues [57], deletion peptides of 
insulin [56] and a deletion peptide of the heat shock 
protein 60 [54] that have been used widely in the 
treatment of diabetes. This has demonstrated the 
potential and importance of peptides as 
pharmacological agents. Additionally, as the number 
of new entities approved by the FDA rapidly 
decreases over the years [64] and the number of 
publicities about the side effects of popular small 
molecules increases (such as the cancer 
chemotherapeutic or COX-2 inhibitors) [65-67], the 
pharmaceutical industry is now reviving their interest 
in peptides as potential drug candidates. With good 
pharmacology properties and new technologies to 
mitigate the weakness of peptides, the number of 
therapeutic peptide candidates will continue to grow. 
Mode of Action for Therapeutic Peptides  
Antiviral peptides that either interact with the 
virus particles or target at critical viral replication 
steps of the life cycle can potentially be used as 
treatment or prophylaxis for dengue. Several 
approaches have been explored thus far to inhibit 
dengue virus infection, including targeting the host 
cell receptors or attachment factors, viral structural 
proteins and non-structural (NS) proteins. Drugs that 
were designed against these three main targets 
employ different mechanisms of action to stop virus 
infection. By targeting the host cellular receptors or 
attachment factors, it will prevent the attachment and 
binding of viral proteins with the host cell, hence 
stopping the subsequent entry of DENV. Drug 
candidates directing at the viral structural proteins 
[capsid (C), pre-membrane (prM/M) and envelope 
(E)], on the other hand, might be able to interfere with 
the binding of viruses to host cells, thereby inhibiting 
the viral attachment/fusion and viral entry. Lastly, as 
non-structural proteins are essential components of 
replication machinery, designing drug candidates 
against NS proteins will interfere with the viral 
replication cycle to effectively ameliorate dengue.  
 
 
Figure 2. Schematic diagram of DENV replication cycle and summary of antiviral peptides. The antiviral peptides are classified according to their mechanism of 
actions, which include entry inhibitors, fusion inhibitors, translation inhibitors and replication inhibitors. 
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Entry inhibitors: Targeting host cells  
One of the attractive approaches to inhibiting 
virus infection is by blocking the cellular receptors or 
attachment factors, or mimicking the cellular 
receptors, hence preventing the virus from attaching 
and entering host cells. This will form the first barrier 
to block viral infection. Studies have shown that this is 
a feasible approach to halting viral infections [68-70]. 
Pugach et al. (2008) and Lieberman-Blum et al. (2008) 
demonstrated that a small molecule, CCR5 inhibitor, 
Maraviroc, successfully inhibited human 
immunodeficiency virus type 1 (HIV-1) infection by 
binding to the CCR5 co-receptor of host cells [68, 69]. 
On the other hand, Myrcludex B, a lipomyristolated 
peptide containing 47 homologous amino acid 
residues of hepatitis B virus pre-S1 protein, was able 
to bind to the NTCP of host cells and resulted in the 
restriction of virion uptake in the host cells [70]. The 
identified DENV receptors or attachment factors on 
mammalian cells were reviewed by Perera-Lecoin et 
al. (2014) and Cruz-Oliveira et al. (2015) [71, 72]. Some 
of the important attachment factors or receptors are 
the dendritic cell-specific intercellular adhesion 
molecule 3-grabbing nonintegrin (DC-SIGN) [34], 
heparan sulfate [73], mannose receptor [74], 
HSP90/HSP70 [75], laminin receptor [76], and the 
TIM and TAM proteins [77]. To date, several small 
molecules were identified as receptor antagonists or 
mimics for DENV. For instance, CC-chemokine 
receptor 5 (CCR5) antagonists, Met-R and UK484900 
(a Maraviroc analogue) prevented CCR5 activation 
and reduced DENV load [78], while heparin sulfate 
mimetics, such as PI-88 [79], fucoidan [80] and CF-238 
[81], were shown to block viral entry. Interestingly, to 
the best of our knowledge, no peptide inhibitors were 
found to block DENV infection by binding to cellular 
attachment factors or receptors. This represents a big 
research gap that should prompt researchers to 
investigate.  
The DC-SIGN is a type II transmembrane protein 
that falls into the category of C-type lectin with an 
extracellular domain that can bind specifically to 
carbohydrates [82]. DC-SIGN has been shown to be an 
essential cellular factor required for the infection of 
ebola virus [83, 84], HIV-1 [85, 86] and human 
cytomegalovirus (CMV) [87] into dendritic cells. 
Studies have also shown that dendritic cells that 
abundantly express DC-SIGN are highly susceptible 
to DENV infection [33, 88, 89]. Tassaneetrithep et al. 
(2003) further validated the importance of DC-SIGN 
as a DENV receptor [34], whereby the transfection of 
DC-SIGN into THP-1 cells resulted in DENV infection 
while dendritic cells blocked with anti-DC-SIGN 
prevented DENV infection [34]. These results suggest 
that DC-SIGN is a feasible target for designing 
therapies that prevent DENV infection. Furthermore, 
dendritic cells were activated after capturing antigen 
and resulted in the stimulation of naïve T cells to 
produce cytokines and chemokines [90]. Blocking the 
binding of DENV to DC-SIGN can prevent DENV 
infection, as well as the initiation of immune response 
which can lead to severe dengue characterized by the 
cytokine storm. Based on the literature, limited 
DC-SIGN inhibitors are found to stop DENV 
infection. In a study, Alen et al. (2011) evaluated the 
inhibitory properties of various carbohydrate-binding 
agents (CBAs) which are mannose-specific plant 
lectins by using the Raji/DC-SIGN+ cell line. Results 
showed that Hippeastrum hybrid (HHA), Galanthus 
nivalis (GNA) and Urtica dioica (UDA) were able to 
bind to the envelope of DENV, hence preventing the 
subsequent viral attachment [91]. Similarly, 
pradimicin-s (PRM-S), a small-size non-peptidic CBA, 
was shown to exert antiviral activity against DENV by 
binding to the DENV envelope in monocyte-derived 
dendritic cells [91].  
Another important known DENV receptor is the 
glycosaminoglycans (GAG). Among the GAG family, 
heparin sulfate (HS) is the most ubiquitous member of 
the family and is the putative receptor for DENV 
[92-94]. Studies have shown that HS acted as the first 
interactive attachment factor to facilitate DENV 
binding to the second receptor [92, 95]. It was 
demonstrated that DENV-HS interacted via positively 
charged E(III) residues, especially Lys291 and Lys 295 
binding to the negatively charged HS [73, 96]. Many 
heparan mimetics were identified to block DENV 
infection [79, 80, 97]. Lee et al. (2006) showed that a 
heparin sulfate mimetic, phosphomannopentaose 
sulfate (PI-88), significantly increased the survival rate 
of DENV-infected mice [79]. In another study, a 
sulphated polysaccharide, fucoidan, which was 
extracted from the marine alga Cladosiphon, was able 
to inhibit DENV-2 infection by binding to the DENV 
envelope protein [80]. Interestingly, Talarico et al. 
(2005) showed that iota-carrageenan and dl-galactan 
hybrid C2S-3 (sulphated polysaccharides isolated 
from the red seaweeds Gymnogongrus griffithsiae and 
Cryptonemia crenulata) inhibited DENV infection in a 
virus serotype and host cell dependent manner [97]. 
Many other heparin mimetics, including CF-238 [81], 
sulphated galactomannan [98], curdlan sulfate [99], 
sulphated galactan [98], sulphated K5 [100] and 
chondroitin sulfate [101], were found to inhibit DENV 
infection but no antiviral peptide was identified to 
either bind to cellular receptor or act as a receptor 
mimetic to block DENV entry thus far. Likewise, to 
the best of our knowledge, no antiviral peptide was 
found to inhibit DENV infection by targeting other 
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receptors, including mannose receptor [74], HSP 
90/70 [75], laminin receptor [76], and the TIM and 
TAM proteins [77]. Furthermore, inhibitors targeting 
host cellular receptor(s) are anticipated to be less 
prone to develop resistance as compared to those 
targeting viruses. Therefore, this may serve as an 
interesting research gap to be explored.  
Although studies demonstrated that DENV 
mainly enters host cells via receptor initiated-clathrin 
mediated endocytosis [102-104], viral entry via 
clathrin-independent endocytic route has also been 
observed [104]. In addition, evidence of direct entry 
via fusion with plasmatic membrane leading to direct 
penetration into cytoplasm without undergoing 
endocytosis has also been described [105, 106]. 
Furthermore, evidence showed that DENV is able to 
infect a variety of cell types, including those isolated 
from humans [107, 108], monkeys [92, 93], hamsters 
[95, 109] and mosquitoes [110, 111] via different 
receptors. Therefore, the DENV entry pathway is 
greatly dependent on the cell type and viral strain. 
Due to the variability in viral entry routes and broad 
tissue tropism, targeting the viral structural proteins 
is easier than the vastly different cellular receptors, as 
DENV possesses the capability to utilize a wide range 
of cellular receptors and pathways to enter host cells. 
Viral structural proteins, especially the E protein, is 
therefore a popular target for antiviral inhibitors to 
interfere with the virus-host interactions and stop 
subsequent viral entry. 
Entry Inhibitors: Targeting Envelope (E) 
proteins 
The viral infection cycle starts with the 
interaction of viral structural proteins, mediated 
mainly by the E protein with the host cell receptors or 
attachment factors to facilitate the entry of virus. The 
DENV E protein is 53 kDa in size and composed of 
three distinct domains, namely the domain I E(I), 
flanked by the dimerization domain E(II) containing 
the fusion peptide and an immunoglobulin-like 
domain E(III) that protrudes from the virion surface, 
followed by a membrane proximal stem and a 
transmembrane anchor (Figure 3) [45, 112].  
 
 
 
Figure 3. Schematic diagram of DENV envelope (E) proteins in their dimeric forms. 
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The function of E(I) has not been fully 
characterized, although it has been shown to be 
involved in the structural rearrangement of the E 
protein during internalization [112]. The E(II) contains 
a region known as fusion peptide, which is 
responsible for the viral fusion activity, and the E 
domain II also contains serotype-conserved epitopes, 
and contributes to the E protein dimerization [113, 
114]. Previous studies have shown the E(III) is 
responsible for receptor recognition, which is essential 
for viral attachment to facilitate viral entry into host 
cells by receptor-mediated, clathrin-dependent 
endocytosis (primary method) [73, 102, 103]. 
Additionally, E(III) also harbours the 
serotype-specific neutralizing epitopes [115, 116]. 
Because of the involvement of receptor recognition 
and attachment, as well as its vital role in mediating 
viral and cellular membrane fusion to release viral 
genomic RNA for viral replication, the E glycoprotein 
is the most important protein facilitating viral entry. 
Hence, this makes the E protein a good antiviral target 
to stop viral entry.  
The DENV E structural proteins have been well 
determined using nuclear magnetic resonance 
spectroscopy, X-ray crystallography and cryo-electron 
microscopy [112, 117, 118]. Recent advancements in 
the understanding of the high-resolution E structure 
have allowed researchers to utilize the information in 
combination with in silico molecular drug designing 
methods to search for potential antiviral candidates. 
Several research groups have utilized different 
strategies including in silico drug design to screen for 
novel antiviral peptides against the E protein (Table 
1). By using Wimley-White interfacial hydrophobicity 
scale (WWIHS) in combination with known structural 
data of the E protein, Hrobowski et al. (2005) were the 
first group to identify a novel peptide DN59, 
corresponding to the stem region of E, which showed 
>99% DENV-2 inhibition at <25 µM [119]. The D59 
peptide was suggested to function through a sequence 
of specific mechanisms as a scrambled peptide failed 
to inhibit DENV infection. It was hypothesized that 
the DN59 peptide might interfere with the 
intramolecular interaction, disrupt structural 
rearrangements of fusion proteins or interact with 
target cell surface components to exert its inhibitory 
effects [119]. The mechanism of action for peptide 
DN59 was further evaluated by a later study (2012) 
where it was shown that the peptide D59 inhibited 
DENV infectivity by interacting directly with virus 
particles, causing the formation of holes at the 
five-fold vertices in the virus particles [120]. This led 
to the release of viral genomic RNA and exposure of 
the viral RNA to exogenous RNase [120].  
Likewise, Schmidt et al. (2010) also hypothesized 
and proved that the stem peptides could inhibit 
dengue virus infection [121]. In the study, a set of 
overlapping peptides based on the DV2 stem region 
(from amino acid residues 396-447) were synthesized 
and tested for their binding affinities with soluble 
form of DV2 E (sE, covering only the first 395 residues 
of E) via fluorescence polarization. Among the set of 
overlapping peptides, a peptide (DV2419-447) was 
found to bind selectively to the post-fusion of sE with 
the concentration of half-maximal change in 
fluorescence polarization (FP IC50) of 0.125 µM and Kd 
at approximately 150 nM, while the scrambled 
peptide DV2419-447 neither bound to pre-fusion nor 
post-fusion conformers of sE. Schmidt et al. (2010) 
proposed that the peptide DV2419-447 inhibited DENV 
infection through a two-step mechanism during 
late-stage fusion intermediate, whereby the peptide 
first binds non-specifically to the viral membrane, 
followed by specific interaction with the E protein 
when E proteins undergo conformational 
rearrangement at low pH. Interestingly, they 
observed that the reduction of the DV2419-447 
hydrophobicity (by changing the 441-447 amino acid 
residues) greatly reduced the inhibitory property of 
the peptide, but not its binding affinity against 
dengue virus E proteins. This suggested the 
importance of peptide hydrophobicity to non-specific 
host membrane interaction before high binding 
affinity to the DENV E protein.  
The importance of hydrophobicity was further 
supported by Hrobowski et al. (2005), whereby the 
novel antiviral peptide was successfully identified 
using the Wimley-White interfacial hydrophobicity 
scale (WWIHS) screening method. This screening 
method calculated a sliding hydrophobicity score to 
determine the segments of the protein with a 
propensity to interact with membrane interfaces [119]. 
By using a similar strategy, another study has 
identified five hydrophobic regions located on the 
DENV-2 E protein [122]. Amino acids derived from 
these regions were screened via WWIHS and further 
optimized using RAPDF biased Monte Carlo method. 
This resulted in the identification of several novel 
peptides, namely DS03/DS04, DS27/DS28 and DS36, 
which could potentially interrupt protein-protein 
interactions during DENV fusion. Likewise, many 
antiviral peptides were identified against other 
viruses such as type-1 herpes simplex virus (HSV-1) 
[122], severe acute respiratory syndrome coronavirus 
(SARS) [123], human cytomegalovirus (HCMV) [124] 
and rift valley fever virus (RVFV) [125] via the same 
approach. This again has validated the importance of 
hydrophobicity property for antiviral peptides.  
In addition, it was observed that many of the 
antiviral peptides known to inhibit entry of enveloped 
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viruses to cells have hydrophobic and/or 
amphipathic properties to facilitate the interaction 
with cellular lipid membrane interfaces [126, 127]. 
Besides using WWIHS, the interfacial helical 
hydrophobic moment (iHHM) is another 
physio-chemical determining strategy which can be 
used to augment the peptide-membrane interfaces. 
This approach quantified the segregation of 
hydrophobic and hydrophilic faces of a peptide 
folded into an α-helix structure [128]. Higher iHHM 
value indicates stronger membrane interaction with 
peptides [129, 130]. Additionally, Badani et al. (2014) 
also suggested hydrophobicity and amphipathicity to 
be critical properties for peptides in their interaction 
with cellular membrane and thereby inhibiting viral 
entry [126]. Therefore, for future drug design and 
development, researchers could consider 
incorporating the hydrophobic and amphipathic 
properties into antiviral peptides to further enhance 
antiviral efficacies. 
Previous studies have shown that the lateral loop 
located on E(III) played an important role in 
virus-host receptor(s) interaction [73, 131], hence 
making it an interesting target. A short sequence 
(380-IGVEPGQLKL-389) in the lateral loop on the 
DENV-2 E(III) was used as a target to screen for 
potential antiviral peptides using the BioMoDroid 
algorithm [132]. Four different peptides were 
designed and DET4 (one of the peptides) was found to 
inhibit 85% DENV-2 at 500 µM. TEM images indicated 
that DET4 inhibited DENV-2 entry by causing 
structural abnormalities and alteration of the 
conformational changes of E proteins. On the 
contrary, Panya et al. (2014) targeted on the 
n-octyl-β-D-glycoside (βOG) hydrophobic pocket 
located in the domain I domain II interface of DV E 
protein [133]. A previous study has shown that the 
shift of two β-hairpins located at the hydrophobic 
pocket was essential to cause correct conformational 
changes during virus fusion step [113]. The 
importance of the βOG hydrophobic pocket was 
further validated as several compounds targeting this 
hydrophobic pocket were able to stop DENV infection 
[134, 135]. By using AUTODOCK v4.2 and CDOCKER 
DISCOVERY STUDIO v2.1 software, Panya et al. 
(2014) found a di-peptide, EF, to be the most effective 
antiviral peptide as it inhibited DENV-2 infection 
with the IC50 value of 96 µM [133].  
Studies have shown that the E stem region was 
well conserved among Flaviviruses [including WNV, 
tick-borne encephalitis virus (TBE), YFV and JEV] 
[121, 136]. Therefore, an antiviral peptide targeting 
against one DENV serotype might possess the 
possibility to inhibit other DENV serotypes and 
closely related Flaviviruses. To further examine this 
hypothesis, Schmidt et al. (2010) investigated the 
antiviral potential of stem peptides derived from 
DENV-2 and WNV against DENV 1, 2, 3 and 4 [136]. 
The amino acid residues from 419-447 of the genome 
of each of the four DENV serotypes were synthesized 
along with a solubility tag (RGKGR). Results showed 
that DV2419-447 remained the strongest inhibitor against 
all four dengue serotypes, followed by DV1419-447, 
DV3419-447 and DV4419-447. Nonetheless, when stem 
peptides (residues 419-447) from related flaviviruses 
were tested against DENV infection, none of these 
peptides inhibited any of the DENV serotypes. This 
might be due to the variation in the seven residues 
located at the C-terminal which could have affected 
the non-specific interaction with the viral membrane 
rather than poor affinity against E protein, as WNV 
had nearly identical binding affinities for trimeric 
DV2 sE [136]. To further validate the observation, 
mutagenesis was performed, confirming that residues 
442-444 were important in conferring the antiviral 
activity of the stem peptide whereby increased 
hydrophobicity would increase inhibitory strength 
[136]. On the other hand, a similar situation was 
observed by Hrobowski et al. (2005), whereby the DN 
59 peptide (peptide sequence corresponding to the 
pre-anchor stem of the E protein and highly 
conserved among flaviviruses) which was shown to 
inhibit DENV had also demonstrated cross-inhibitory 
activity against WNV (>99% inhibition with 
concentration of <25µM) [119].  
Bai et al. (2007) found a peptide, P1, which was 
isolated from the murine brain cDNA phage display 
library by biopanning against the recombinant WNV 
E protein [137]. When P1 was tested against DENV-2, 
it inhibited ~99% DENV-2 at a concentration of 200 
µM. Surface plasmon resonance (SPR) showed that P1 
bound to the WNV E protein with a Kd of 6 µM. 
However, the specific binding site on E protein and 
the mode of action are unknown. Other peptides that 
blocked DENV infection by binding to the E proteins 
were DN57 opt and 1OAN1 [138]. In the study, a set 
of peptides were computationally designed based on 
the pre-entry dimeric E structure. Peptides DN57 and 
1OAN1 specifically designed from the hinge of 
domain II and the first domain I/domain II 
connection, was shown to display IC50 of 8 and 7 µM, 
respectively [138]. Both peptides were shown to bind 
specifically (affinities ~1 µM) to the purified DENV-2 
E protein. Images from cryoEM suggested that these 
peptides might have caused structural deformations 
to the DENV-2 surface, hence interfering the 
virus-host cell binding. Further study of peptide 
inhibitors 1OAN1 and DN59 has also revealed that 
both peptide inhibitors were able to inhibit the 
antibody dependent enhancement (ADE) effect in 
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vitro with an IC50 of 3 µM and 6 µM, respectively [139]. 
In a recent study, Chew et al. (2015) identified a novel 
peptide, peptide gg-ww, by biopanning a randomised 
phage display peptide library against the purified 
DENV-2 viral particles [140]. Approximately 96% 
inhibition was achieved at the concentration of 250 
µM and the data indicated that peptide gg-ww 
inhibited DENV-2 entry. On the other hand, screening 
of commercial cyclic peptides through molecular 
docking resulted in the identification of a peptide, the 
brain natriuretic peptide fragment 7-32 (BNP7-32), 
which could bind to the E protein with a pKi value of 
32.7 and ΔG of -44.9 kcalmol-1 [141]. Due to the fact 
that data were obtained via in silico design, further 
experiments were required to explore the inhibitory 
potential of the peptide against DENV.  
Entry Inhibitors: Targeting prM/M and C 
proteins 
Many studies have focused on the DENV E 
protein due to the nature of the virus structure, 
whereby the E proteins cover most of the surface area 
of the viral particle [112], and the vast and expanded 
knowledge on the E protein. Nonetheless, prM and C 
proteins are feasible targets to look into in the 
screening for antiviral peptides.  
The prM protein (about 21 kDa) is the precursor 
of the M protein (approximately 8 kDa). The cleavage 
of the prM protein by the cellular protease (furin) 
would separate the prM protein into the “pr” peptide 
(1-91 residues), the ectodomain (92-130 residues) and 
the M protein (131-166 residues) [45, 142, 143]. The 
hydrophilic N-terminal region of the protein is 
responsible for coding the glycosylated “pr” segment 
of the prM protein. The prM is believed to protect the 
E protein from conformational changes during the 
maturation pathway in the acidic environment of the 
trans-golgi network. A previous study has shown that 
prM-containing-virus is more resistant to the low pH 
environment [144]. Upon release of the matured 
virions, “pr” will be separated, leaving the E and M 
proteins on the surface of the mature DENV. In a 
recent study, a peptide inhibitor (MLH40) mimicking 
the conserved ectodomain of the M protein was 
designed and it was shown to inhibit all four DENV 
serotypes with an IC50 of 24–31 µM [145]. Docking 
results indicated that MLH40 bound to the interior 
site of E homodimer, which is the same interacting 
site for the native M protein against the E protein. 
Additionally, the expression of the pr protein also 
successfully inhibited virus fusion at low pH and 
stopped viral infection [146]. Approximately 81–85% 
inhibition was achieved at 30 µM. Data indicated that 
the pr peptide interacted with a highly conserved 
histidine (H244) because the substitution of H244 to 
alanine had led to the disruption of the pr-E 
interaction [146]. This disruption could have resulted 
in a distorted E conformation, therefore interfering 
the pH-triggered fusion reaction in the endosome. 
Further optimization could be carried out using 
truncated pr peptides to identify the amino acid 
residues that are essential to block viral infection.  
On the other hand, the DENV C protein 
(approximately 11 kDa) is composed of four α-helical 
regions arranged in antiparallel homodimers [147]. 
The structure of the C protein contains high net 
charge with an asymmetric distribution of basic 
residues which lie along the surface of the C protein to 
orchestrate RNA binding. In contrast, the opposite 
surface forms a hydrophobic region which may 
enable interactions with lipids [147, 148]. This 
configuration makes the C protein essential in virus 
assembly as it enables encapsulation of the ssRNA 
genome to form the nucleocapsid [45]. Despite a 
general understanding of the viral RNA assembly 
role, it is believed that the hydrophobic region of the 
C-terminal capsid protein contains a signal sequence 
for anchoring the protein into the endoplasmic 
reticulum (ER) membrane and partitioning the prM 
protein to the membrane [143, 149]. The C-terminal is 
then cleaved off by the viral NS2B-NS3 protease to 
form a mature protein during virus assembly [148]. 
Faustino et al. (2015) have designed a peptide 
inhibitor, pep14-23, based on the conserved region of 
DENV C protein. The pep14-23 was able to interfere 
with the interaction of the DENV C protein with the 
host intracellular lipid droplet, which was shown to 
be essential for viral particle formation [46, 150]. It 
was found that the binding forces between the C 
protein and lipid droplets were reduced from 33 pN 
to 19 pN with the addition of 100 µM pep14-23. 
Interestingly, despite the importance of the C protein 
for viral survival, limited antiviral peptide was 
designed against the C protein. This is a target worth 
looking into.  
Replication and Translation Inhibitors: 
Targeting NS proteins  
Viral proteases have been shown to serve as 
good inhibitory targets. For instance, protease 
inhibition was shown to be a successful strategy in 
treating HIV infection [151]. The HIV-1 protease 
cleaves the translated polypeptide chain into smaller 
functional proteins, thereby allowing the virus 
particle to mature [152]. By inhibiting the protease, the 
immature virus particles would not be able to 
transform into the mature virion, hence obstructing 
the viral replication. Several HIV-1 protease inhibitors 
were discovered and used clinically, such as 
saquinavir, ritonavir, indinavir, nelfinavir, 
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amprenavir (and its prodrug, fosamprenavir), 
lopinavir, atazanavir, and darunavir [153]. Similarly, 
the NS5, NS3 and NS2B (co-factor) proteins were 
known to play major roles in enzymatic activities for 
DENV infection, thus making them ideal antiviral 
targets [154, 155]. After DENV infection, translation of 
the viral genome will give rise to a polyprotein 
containing three structural and seven non-structural 
proteins. The polyprotein will be cleaved into 
individual proteins during virus maturation by the 
host proteases (signalase and furin) on the luminal 
side of the endoplasmic reticulum, as well as by the 
viral serine protease (NS2B-NS3 protease) on the 
cytoplasmic side to ensure the success of viral 
replication and maturation [49, 154, 156]. DENV NS3 
contains a trypsin-like protease and it requires the 
NS2B cofactor to be active to cleave the DENV 
polyprotein at the Ser-His-Asp catalytic triad 
[157-160].  
In a previous study, Schuller et al. (2011) 
synthesized a series of tripeptide aldehyde inhibitors 
whereby four of them had the IC50 values in the range 
between ~6.7 and 12.2 µM against the DENV-2 
NS2B-NS3 protease [161]. Among the four tripeptide 
aldehyde inhibitors, tripeptide 1 (benzoyl-n-Lys-Arg- 
Arg-H) and tripeptide 2 (phenylacetyl-Lys- 
Arg-Arg-H) were reported to have the most potential 
as anti-DENV candidates with IC50 of 9.5 µM and 6.7 
µM, respectively [162]. Further investigation of the 
tripeptide1 revealed that it bound covalently to the 
DENV-3 NS2B-NS3 protease and resulted in the 
formation of a closed conformation of the NS2B-NS3 
protease in which the hydrophilic β-hairpin region of 
NS2B would wrap around the NS3 core [163]. 
Structural analysis of this protease-peptide complex 
further revealed a pocket located on the NS2B-NS3 
protease which could act as a new antiviral target for 
drug development [163]. Another protease inhibitor, 
aprotinin, a large polypeptide [also known as bovine 
pancreatic trypsin inhibitor (BPTI)] was hypothesized 
to form multiple interactions with the NS2B-NS3 
protease and gained its inhibitory activity from the 
steric hindrance of the active site [163]. In contrast to 
tripeptide 1 which required the interactions with 
NS2B, no direct binding was observed between 
aprotinin and NS2B [163].  
In a recent study, several cyclic peptides were 
designed based on the binding loop of aprotinin 
which is highly similar to the sequence of the native 
NS2B-NS3 cleavage site and extends from the P3 to 
P4’ position at the active site of the NS2B-NS3 
protease [164]. Results indicated that a peptide, CP7, 
was able to show good inhibitory property (Ki value 
of 2.9 µM) against the DENV-3 protease. Similar with 
the binding of aprotinin to the protease, strong 
hydrogen bonds contributed by the P1 and P2’ 
positions were observed but the inhibitory constant 
value was not as strong as aprotinin (Ki of 0.026 µM). 
This might be due to the flexibility of the cyclic 
peptide which resulted in the decreased affinity 
against the protease. Nevertheless, this study proved 
the feasibility of designing inhibitors against both 
prime and non-prime regions of the protease, and CP7 
could act as an alternative candidate for developing a 
therapeutic against the NS2B-NS3 protease.  
On the other hand, the N-benzoyl capped 
tetrapeptide sequence (Nle-Lys-Arg-Arg) was 
previously shown to be the favoured amino acid 
residues for the S1-S4 subsites of the NS2B-NS3 
protease binding cavity [165, 166]. Yusof et al. (2000) 
showed that the Arg-Arg residues in the P1 and P2 
positions located next to the cleavage site were 
responsible for the high binding affinity against the 
protease, while Li et al. (2005) found that Lys and Nle 
(norleucine) in the P3 and P4 positions were essential 
for high binding affinity [165, 166]. Interestingly, 
Nitsche et al. (2012) showed that the removal of an 
arginine resulted in better inhibitory activity [167]. 
Nitsche et al. (2012) showed that a retro-peptide 
based on the sequence R-Arg-Lys-Nle-NH2 with an 
arylcyano-acrylamide group as N-terminal cap 
possessed the best inhibition activity at Ki value of 4.9 
µM [167]. It is hypothesized that the 
arylcyanoacrylamide moiety mimic the first Arg in 
the P1 position while the Arg-Lys-Nle tripeptide 
bound to other protein pockets of NS2B-NS3 protease. 
Unfortunately, even though the drug candidate 
possessed good binding ability, it did not have 
significant antiviral activity in the cell culture against 
DENV. Therefore, Nitsche et al. (2013) further 
optimized the lead candidate via structure activity 
relationship assays in a subsequent study and 
successfully developed a thiazolidinedione-based 
peptide hybrid (hybrid 24b) containing a hydrophobic 
group with a better Ki value of 1.5 µM [168]. 
Nonetheless, drugs designed via structure-based 
activity faced the limitation due to the differences in 
protease structures derived from crystallization 
versus the in vivo protease structures, thereby the 
antiviral candidate which has high binding affinity 
against the crystallized protease structure might not 
have the same binding affinity against the protease in 
vivo. To overcome this challenge, Nitsche et al. (2013) 
further modified the N-terminal cap moieties and 
incorporated membrane-permeable peptide to 
increase the potential antiviral activities [168]. The 
peptide hybrid which possessed the best antiviral 
activity in the cell culture was found to be the 
rhodanine-based peptide hybrid 10a with an EC50 
value of 16.7 µM and Ki value of 9.3 µM. From the 
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study, the Arg-Lys residues were found to be 
sufficient to create high target affinity with Ki values 
below 2 µM.  
On the other hand, Behnam et al. (2015) utilized 
the Bz-Arg-Lys-Nle as the core sequence to further 
optimize the chemical structure to improve its 
antiviral potential against the NS2B-NS3 protease 
[169]. Tripeptide hybrid 83 was created by the 
combination of 4-CF3-benzyl ether and the thiazole 
cap, while tripeptide hybrid 86 was created by the 
combination of 4-CF3-benzyl ether and the thien-2-yl 
cap. Both of the peptide hybrids successfully showed 
improved Ki values of 12 nM and 19 nM, respectively. 
Thus far, these are the two peptide hybrids which 
possess the highest binding affinity against the 
NS2B-NS3 protease. Nonetheless, the derivative 83 
which possessed the highest binding affinity had a 
lower EC50 value of 20 µM in reducing the virus titer 
as compared to the derivative 86 (EC50 value of 7 µM) 
while the derivative 104 and derivative 90 were found 
to have the most potent EC50 value of 3.42 µM and 4.06 
µM, respectively. Theoretically, the inhibitor which 
has a higher binding affinity against a target would 
result in a higher antiviral property. But in contrast to 
the direct in vitro protein-peptide interaction assay, 
cellular antiviral assay in the cell culture is 
complicated by factors such as membrane 
permeability and metabolic stability. Data suggested 
that the lipophilicity of the tripeptide hybrids 
correlated well with the observed cellular antiviral 
activities which might be influenced by the fact that 
higher polarity (lower lipophilicity) could lead to 
weaker membrane permeability [169]. In this case, the 
tripeptide hybrid 104 was shown to be more lipophilic 
than the tripeptide hybrid 83. Moreover, data also 
indicated that the tripeptide hybrid 104 possessed a 
much higher half-life of 175 minutes compared to the 
tripeptide hybrid 83 (half-life of 45 minutes) in 
metabolic clearance via rat liver microsomes. These 
observations might offer the possible explanation of 
the higher antiviral activity of the tripeptide hybrid 
104 in cellular assays as compared to the analogue of 
tripeptide hybrid 83 which possessed higher binding 
ability against DENV-2 protease in vitro.  
In another study, 15 peptide inhibitors against 
the NS2B-NS3 protease were modified via molecular 
modelling method [170]. Results from the ADME/Tox 
calculation indicated that the peptide inhibitor 11 
(Bz-Nle-Lys-Arg-Bip) possessed the best 
pharmacokinetic properties among all inhibitors due 
to its ability to be better absorbed into the intestine 
and to remain inactive in the central nervous system 
[170]. This results supported the use of 
Bz-Nle-Lys-Arg as the lead candidate for drug 
development against DENV by targeting the 
NS2B-NS3 protease. On the other hand, several 
hexapeptides derived from the NS2B-NS3 protease 
cleavage sites were synthesized and they were shown 
to inhibit DENV in a low micromolar range [171]. 
Among all candidates, the best hexapeptide inhibitor 
was derived from the NS2A/NS2B region with a Ki 
value of 12 µM. Likewise, several peptidic α-keto 
amide inhibitors mimicking the NS3/NS4 region 
were designed and two of the peptidic inhibitors were 
found to inhibit the NS3 protease with Ki values of 16 
and 47 µM, respectively [172]. 
Tambunan and Alamudi (2010) designed several 
cyclopentapeptides based on the substrate specificity 
for the NS2B-NS3 protease and a cyclopentapeptide, 
CKRKC, was found to be the best candidate with the 
estimated free binding energy of -8.39 kcal/mol and 
Ki of 0.707 μM [173]. Nonetheless, the 
cyclopentapeptide was designed in silico, further in 
vitro and cell-based experiments were required to 
further exploit the inhibitory potential of the peptide 
against DENV. Similarly, Velmurugan et al. (2014) 
found a hexapeptide with the highest binding energy 
of -80.4 kcal/mol against the NS2B-NS3 protease, but 
further investigation is required to verify its antiviral 
potential via in vitro studies [174]. In another study, a 
natural peptide library composed of conotoxins (a 
mixture of peptide neurotoxins produced by cone 
snails) was used to screen against the DENV 
NS2B-NS3 protease [175]. A 13-mer cyclic peptide 
inhibitor, MrIA (derived from Conus marmoreus), was 
shown to possess a Ki value of 9 µM. Mutagenesis 
study further revealed that the inhibitory activity was 
mainly mediated by a disulphide bond loop with a 
Lys residue at the active site. As the NS2B-NS3 
protease was previously shown to have a preference 
for Ser at the P’ position, further optimization was 
carried out. By changing the Leu to Ser, the resultant 
peptide 7 (P7) and peptide 9 (P9) were shown to have 
stronger inhibitory activities with improved Ki values 
of 1.4 µM and 2.2 µM, respectively. Nonetheless, 
stability assays showed that about half of the 
inhibitory activity of P7 was lost after 2.5h, while only 
~25% inhibitory activity of P9 was lost after 
incubating with protease for 2.5h. Although P9 had a 
higher Ki value of 2.2 µM as compared to P7 (1.4 µM), 
the stability of P9 to withstand protease degradation 
and its efficient cell permeability in BHK-21 and Vero 
cells had shown that P9 is a better drug candidate. 
Rothan et al. (2012a and 2012b) identified two antiviral 
peptides, namely protegrin-1 and retrocyclin-1 
against DENV NS2B-NS3 protease [176, 177]. It was 
previously shown that protegrin-1, a cationic cyclic 
peptide, possessed broad antimicrobial properties 
against different microorganisms [178]. In addition to 
having good binding affinity (Ki value of 5.85 μM) 
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against the DENV NS2B-NS3 protease, protegrin-1 
was able to inhibit DENV replication in Rhesus 
monkey kidney (MK2) cells with an IC50 of 11.7 μM 
[176]. On the contrary, retrocyclin-1, a circular cationic 
peptide, was shown to inhibit the NS2B-NS3 protease 
at an IC50 of 21.4 μM [177]. Results indicated that 
retrocyclin-1 worked best when incubated with 
DENV-2 during simultaneous treatment, giving 85% 
reduction in viral replication after 75 hours. These 
findings suggest that both protegrin-1 and 
retrocyclin-1 are feasible candidates to be potential 
therapeutic drugs for dengue treatment.  
NS5 is a large multifunctional protein which 
plays an important role in viral replication and 
modulation of the host immune response. It contains 
RNA-dependent RNA polymerase domain at the 
C-terminal end which is essential for viral replication 
and methyltransferase at the N-terminal region for 
RNA capping [155, 179]. These functions are essential 
for viral replication, thereby making NS5 a promising 
target for antiviral drug development. Inhibiting the 
polymerase or methyltransferase function can actively 
suppress virus growth and propagation in host cells 
[180]. Both NITD-008 and Balapiravir are examples of 
nucleoside inhibitors, whereby NITD-008 corresponds 
to an adenosine analogue while balapiravir is another 
nucleoside analogue originally developed for the 
treatment of hepatitis C virus. However, NITD-008 
was terminated due to severe side effects while 
balapiravir failed due to its low efficiency in clinical 
trials [21, 22]. To search for novel antiviral peptide 
against the NS5 methyltranserase, Tambunan and 
colleagues (2014) screened over 300 commercial cyclic 
peptides and molecular docking results revealed two 
potential ligands, namely, tyr123-Prepro Endothelin 
(110-130) and urotensin II [181]. Both peptides were 
shown to bind to the NS5 methyltranserase and 
formed stable complexes. Docking results suggested 
that tyr123-Prepro Endothelin (110-130) was found to 
bind to the S-adenosyl-L-methionine (SAM) site of 
NS5 with a ΔG of -24.73 kkal/mol while urotensin II 
bound to the RNA-cap site of NS5 with a ΔG of -19.04 
kkal/mol. Nevertheless, further in vitro verification is 
required to elucidate the antiviral potential of these 
inhibitors. Despite the importance of the NS5 protein, 
there are limited antiviral peptide screening studies 
targeting the NS5 protein. Perhaps this is due to the 
lack of a crystal structure that contains the full length 
of the NS5 protein. With the recent publication of the 
crystal structure of the NS5 protein [182], 
development of antiviral peptide targeting the NS5 
protein can be expected.  
Limitations of Antiviral Peptides  
There are a number of limitations that hinder the 
use of peptides as therapeutic drugs. The main 
challenges are due to the poor stability and 
bioavailability of peptides. Unmodified peptides were 
shown to commonly degrade quickly in human 
serum, resulting in low in vivo activities [183, 184]. 
Nonetheless, various chemical modifications can be 
applied to manipulate the physicochemical properties 
of peptides, thereby increasing the stability and 
bioavailability of the peptides. These chemical 
modification approaches have been reviewed by 
Gentilucci et al. (2010) [53]. For instance, conjugation 
to polymers such as polyethylene glycol (PEG) 
increased the molecular weight of peptide, hence 
enhancing its peripheral stability to undergo 
hydrolysis in the brain [185]. A previous study also 
showed that the half-lives of unmodified peptides of 
less than 0.5 hour could be increased to approximately 
1.5 hour after C-amidation and N-acetylation, while 
cyclization successfully increased the half-lives of the 
peptides to 6.5 hours [186]. On the other hand, the 
replacement of arginine residues with an amino acid 
derivate of arginine, α-amino-3-guanidino-propionic 
acid (Agp), could dramatically reduce the cleavage of 
peptide by trypsin [187]. The substitution of L-amino 
acids to D-amino acids of pandinin-2 increased its 
resistance to the degradation by bovine pancreatic 
trypsin and human elastase. The stability of the 
D-amino acid substituted pandinin-2 was increased to 
4 hours as compared to L-pandinin-2 which was 
rapidly cleaved by these two enzymes [188].  
Additionally, multiple strategies could also be 
incorporated into peptide drug development to 
enhance the antiviral properties of peptides. These 
include the mutagenesis assays to identify the vital 
amino acids which are responsible for the inhibitory 
effects and the addition of cell penetrating peptides to 
increase the cell permeability of peptides. For 
example, the IC50 of two antiviral peptides (DN57 opt 
and DN81 opt) were successfully reduced to 8 μM and 
40 μM, respectively, after amino acid optimization 
was performed via residue-specific all-atom 
probability discriminatory function approach [119, 
138]. Similarly, Schmidt and co-workers (2010a, 
2010b) successfully enhanced the antiviral properties 
of the identified peptides after optimizations via 
mutagenesis assays and the addition of a solubility 
tag [121, 136]. On the other hand, due to the 
hydrophilicity and conformation properties of 
peptides, cellular uptake of peptides is constrained 
[189, 190]. Oral bioavailability of peptides is therefore 
limited by the membrane barrier. To overcome this 
challenge, cell-penetrating peptides (CPP) can be 
incorporated into the peptide sequence to act as a 
cargo delivery in carrying antiviral peptide across the 
permeability barrier and entering cells to exert its 
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inhibitory activity [191]. For instance, by conjugating 
the tat peptide (derived from the HIV-1 
transcriptional activator protein) to galactosidase 
protein, it enabled the delivery of the fusion protein to 
all the tissues in mice while those without tat 
peptide-conjugated were restrained [192]. With the 
advancement of technology, the drawbacks of 
peptides serving as antiviral agents can therefore be 
overcome by various strategies. This, in turn, will aid 
the development and use of peptides as therapeutics.  
Conclusions 
The development of peptides as therapeutic 
drugs against viruses is a promising field for drug 
discovery. Peptides are known to be highly specific 
and selective against targets, have lower toxicity and 
low accumulation in tissues, all of which make them 
good candidates for drug development [193]. This 
phenomenon is in contrast to small molecule drugs, 
whereby off-target and toxicity are some of the 
biggest drawbacks for small molecule drugs [194, 
195]. Although peptides possess several limitations, 
these could be overcome via chemical modifications.  
Many peptides are shown to be effective as they 
demonstrated good in silico and in vitro binding 
affinity against viral targets (Table 1 and 2). However, 
many of these antiviral peptides against DENV have 
not been tested in cell-based assays and none of them 
has been evaluated in any in vivo study. Therefore, 
further studies should focus on elucidating the 
antiviral potential of these peptides in animal models, 
such as the AG129 mice which are highly susceptible 
to DENV infection as they lack both type I and type II 
IFN receptors [196-198]. Furthermore, an ideal DENV 
inhibitor will need to be effective against all four 
DENV serotypes. The inhibitory potential against all 
DENV serotypes have not been explored by many of 
the studies described in this review. With just a few 
exceptions, the mechanisms of inhibition of most of 
the peptides are not well defined. These are the areas 
where further studies should be performed to exploit 
the potential of these antiviral peptide candidates. 
Moreover, the commercially available vaccine 
(CYD-TDV) is unable to achieve the maximal 
protection against all four DENV serotypes, while the 
vector control strategy has failed to reduce the spread 
of DENV. Peptide inhibitors targeting host cells, viral 
structural proteins or non-structural proteins may 
help to overcome dengue infection. With effective 
antivirals, vaccination and vector controls such as 
fogging, dengue in endemic countries can be better 
controlled and the state of public health can be 
improved. 
Table 1. List of antiviral peptides against DENV structural proteins  
Peptides DENV 
serotypes 
Sequences Inhibitory activities Target References 
DN59 All serotypes MAILGDTAWDFGSLGGVFTSIGKALHQVFGAIY IC50 less than 10µM for all serotypes Envelope [119,120]  
P1 DENV-2 DTRACDVIALLCHLNT 200 µM (~99.3% inhibition) Envelope  [137] 
DV2419-447 All serotypes AWDFGSLGGVFTSIGKALHQVFGAIYGAA (solubility 
tag-RGKGR) 
FP IC50 of 0.125µM (DENV-2) Envelope [121, 136] 
DV2419-440 All serotypes AWDFGSLGGVFTSIGKALHQVF FP IC50 of 0.25µM (DENV-2) Envelope [121] 
DV2413-447 All serotypes AILGDTAWDFGSLGGVFTSIGKALHQVFGAIYGAA FP IC50 of 0.275µM (DENV-2) Envelope [121] 
DV2413-440 All serotypes AILGDTAWDFGSLGGVFTSIGKALHQVF FP IC50 of 0.25µM (DENV-2) Envelope [121] 
DV2413-435 All serotypes AILGDTAWDFGSLGGVFTSIGKA FP IC50 of 2 µM (DENV-2) Envelope [121] 
DV1419-447 All serotypes AWDFGSIGGVFTSVGKLVHQVFGTAYGVL (solubility 
tag-RGKGR) 
IC 90:  
DV1- 1.5 µM; DV2- 2 µM 
DV3- >6 µM; DV4- >6 µM 
Envelope [136] 
DV3419-447 All serotypes AWDFGSVGGVLNSLGKMVHQIFGSAYTAL (solubility 
tag-RGKGR) 
IC 90:  
DV1- 0.1 µM; DV2- 2 µM 
DV3- 4 µM; DV4- 1.5 µM 
Envelope [136] 
DV4419-447 All serotypes AWDFGSVGGLFTSLGKAVHQVFGSVYTTM (solubility 
tag-RGKGR) 
IC 90:  
DV1- 5 µM; DV2- 6 µM 
DV3- >6 µM; DV4- 6 µM 
Envelope [136] 
DN57opt DENV-2 RWMVWRHWFHRLRLPYNPGKNKQNQQWP 8 µM Envelope [138] 
1OAN1  DENV-2 FWFTLIKTQAKQPARYRRFC 7 µM Envelope [138] 
DN81 opt DENV-2 RQMRAWGQDYQHGGMGYSC 36 µM Envelope [138] 
DS03opt DENV-2 FPFDFHHDRYYHFHWKRYQH na Envelope [122] 
DS04opt DENV-2 IWWRPRDWPTFIFYFREWRW na Envelope [122] 
DS27opt DENV-2 KEYFRRFFHCHNHQREWHWH na Envelope [122] 
DS28opt DENV-2 KEKRREWEWRFRWEFRLYFE na Envelope [122] 
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DS36opt DENV-2 RHWEQFYFRRRERKFWLFFW na Envelope [122] 
DET4 DENV-2 AGVKDGKLDF 35 µM Envelope [132] 
EF DENV-2 EF 96 µM Envelope [133] 
Pgg-ww DVEN-2 GGARDAGKAEWW IC50 of ~77 -91 µM Envelope [140] 
MLH40 DENV SVALVPHVGMGLETRTETWMSSEGAWKHVQRIETWILRHPG IC50 of 24-31µM Pre-Membrane [145] 
pr DENV-1 and 
DENV-2 
pr protein 30 µM (81-85% inhibitions) Pre-Membrane [146] 
Pep14-23 DENV NMLKRARNRV Binding forces were reduced to 19pN 
from 33pN with the addition of 100 µM 
pep14-23 
Capsid [150] 
DENV: Dengue virus; na: not available 
Table 2. List of antiviral peptides against DENV non-structural proteins  
Peptides DENV 
Serotypes 
Sequences Inhibitory activities Target References  
Tripeptide 2 DENV-2 Phenylacetyl-K-R-R-H IC50 of 6.7 µM NS2B-NS3 [161] 
Tripeptide 1 DENV-2 Benzoyl-n-K-R-R-H 
(n=norleucine) 
IC50 of 9.5 µM NS2B-NS3 [161-163] 
Tripeptide 12 DENV-2 4-Aminophenylacetyl-K-R-R-H IC50 of 11.2 µM NS2B-NS3 [161] 
Tripeptide 11 DVEN-2 4-Phenylphenylacetyl-K-K-R-H IC50 of 12.2 µM NS2B-NS3 [161] 
Aprotinin DENV-3 RPDFC LEPPY TGPCK ARIIR YFYNA KAGLC QTFVY 
GGCRA KRNNF KSAED CMRTC GGA 
Ki of 0.026 µM NS2B-NS3 [163] 
Peptidic α-keto amide 4 DENV-2 Ac-FAAGRR-CHO Ki of 16 µM NS2B-NS3 [172] 
Peptidic α-keto amide 1 DENV-2 Ac-FAAGRR-αketo-SL-CONH2 Ki of 47 µM NS2B-NS3 [172] 
Hexapeptide-1 DENV Ac-RTSKKR-CONH2 Ki of 12 µM NS2B-NS3 [171] 
CP7 DENV-3 PCRARIYGGCA Ki of 2.9 µM NS2B-NS3 [164] 
Tripeptide hybrid 83 DENV-2 Bz-Arg-Lys-L-Phg-NH2 by the combination of 
4-CF3-benzyl ether and thiazole cap 
Ki value of 12 nM; EC50 value of 20 
µM 
NS2B-NS3 [169] 
Tripeptide hybrid 86 DENV-2 Bz-Arg-Lys-L-Phg-NH2 by the combination of 
4-CF3-benzyl ether and thien-2-yl cap 
Ki value of 19 nM; EC50 value of 7 
µM 
NS2B-NS3 [169] 
Tripeptide hybrid 104 DENV-2 Bz-Arg-Lys-L-Phg-NH2 by the combination of 
3-OCH3-benzyl ether and bithiophene cap 
EC50 value of 3.42 µM NS2B-NS3 [169] 
Peptide inhibitor 11 
(BDBM50175978) 
 
DENV-2 Bz-Nle-Lys-Arg-Bip Ki value of 1.16E+4 nM NS2B-NS3 [162, 170] 
Cyclopentapeptide 
CKRKC 
DENV-2 CKRKC Ki of 0.707 μM NS2B-NS3 [173] 
Hexapeptide-2 DENV-2 AIKKFS Glide energy -80.4kcal/mol NS2B-NS3 [174] 
Retro tripeptide hybrid 11 DENV-2 R-Arg-Lys-Nle-NH2 with an arylcyano-acrylamide group 
as N-terminal cap 
Ki value of 4.9 µM NS2B-NS3 [167] 
peptide hybrid 10a DENV-2 Rhodanine-based peptide hybrid bearing a cyclohexyl 
moiety at the heterocycle 
EC50 value of 16.7 µM NS2B-NS3 [168] 
peptide hybrid 24b DENV-2 thiazolidinedione-based peptide hybrid Ki value of 1.5 µM; IC50 value of 2.9 
µM 
NS2B-NS3 [168] 
P7 DENV-2 CGKRKSC Ki value of 1.4 µM NS2B-NS3 [175] 
P9 DENV-2 CAGKRKSG Ki value of 2.2 µM NS2B-NS3 [175] 
Protegrin-1 DENV-2 RGGRLCYCRRRFCVCVGR IC50 of 11.7 μM NS2B-NS3 [176] 
Retrocyclin-1 DENV-2 GICRCICGRGICRCICGRIGGRVPGVGVPGVGHHHHHH IC50 of 21.4 μM NS2B-NS3 [177] 
tyr123-Prepro Endothelin 
(110-130) 
DENV-2 CQCASQKDKKWSYCQAGKEI ΔG of -24.73 kkal/mol NS5 [181] 
Urotensin II DENV-2 ETPDCFWKYCV ΔG of -19.04 kkal/mol NS5 [181] 
DENV: Dengue virus; NS: non-structure 
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